Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, September 16, 2014
Technology Networks
 
Register | Sign in
Home Page
  News
Return

Identified a Key Protein in Maintaining the Identity of B Lymphocytes

Published: Monday, June 10, 2013
Last Updated: Monday, June 10, 2013
Bookmark and Share
This finding could be useful for the study of blood diseases such as lymphoma and leukemia.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Blocking One Receptor on Cells Could Halt Rheumatoid Arthritis
Researchers uncovered multiple pathological processes driven by the activation of the receptor.
New Defence Mechanism Against Viruses Discovered
Mechanism may represent one of the oldest defence mechanisms against viruses in evolutionary history.
Novel Immunotherapy Breast Cancer Vaccine
Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients.
Cell ‘Memory’ Could be Key to Strengthen Vaccine Efficacy
Virginia Tech Carilion Research Institute scientists uncover immune system secret.
Apitope Treatment Approach Published in Nature Communications
Scientists discover how to 'switch off' autoimmune diseases.
NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus
The antibody, 35O22, prevents 62 percent of known HIV strains from infecting cells in the laboratory.
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
‘Switching off’ Autoimmune Diseases
Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases by revealing how to stop cells attacking healthy body tissue.
Understanding and Improving the Body's Fight Against Pathogens
A*STAR scientists find new targets for modulating antibody response.
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv